DNX-2401 adenovirus - Revision history

Lazy at 08:29, 18 January 2025

2025-01-18T08:29:09Z

← Older revision		Revision as of 01:29, 18 January 2025
Line 13:		Line 13:
	with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance		with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance
	for type-1 anti-tumor immune responses.		for type-1 anti-tumor immune responses.
	}}		\|overview=DNX-2401 is a modified adenovirus used in oncolytic virotherapy, demonstrating promising results in a phase 1 trial for recurrent high-grade glioma patients at MD Anderson, with three patients achieving complete, durable responses lasting 29 to 42 months and showing significant immune responses. Preliminary findings were presented at the November 2014 SNO conference, highlighting no adverse events related to the virus.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:46:48Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:46, 12 November 2024
Line 3:		Line 3:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=DNX-2401 adenovirus		\|drug_name=DNX-2401 adenovirus
	\|~~category~~=Oncolytic virotherapy		\|treatment_category=Oncolytic virotherapy
	\|book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO		\|book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO
	trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor.		trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor.

Lazy: Created page with " {{TreatmentInfo |drug_name=DNX-2401 adenovirus |category=Oncolytic virotherapy |book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma patients had been treated, with no adverse event..."

2024-04-06T04:18:19Z

Created page with " {{TreatmentInfo |drug_name=DNX-2401 adenovirus |category=Oncolytic virotherapy |book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma patients had been treated, with no adverse event..."

New page

{{TreatmentInfo
|drug_name=DNX-2401 adenovirus
|category=Oncolytic virotherapy
|book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO
trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor.
Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented
at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma
patients had been treated, with no adverse events attributable to the virus being reported.
3 of 25 patients responded to the treatment with complete, durable responses of 42, 32,
and 29 months so far. These three complete responders had vigorous immune responses,
with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance
for type-1 anti-tumor immune responses.
}}